Biogen
NEWS
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Biogen announced new data from the NURTURE trial of pre-symptomatic patients with spinal muscular atrophy (SMA).
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
The FDA recently approved the combination of Imbruvica-Rituximab for treating chronic lymphocytic leukemia. Here’s everything you need to know.
Today, Biogen presented its first-quarter earnings for 2020, and one of the announcements was that although the company had begun to submit parts of the BLA, they did not expect to complete it until the third quarter of this year.
The discovery that immune T cells have a spectrum of responsiveness could shed light on how our immune system responds to infections and cancer, and what goes wrong in immune diseases.
JOBS
IN THE PRESS